Life-Saving CAE Air1 Ventilator Receives Health Canada Certification

CAE Air1 ventilator has been certified by Health Canada. The news was announced today by CAE.

CAE Air1 ventilator is made-in-Canada ventilator is destined for hospitals across the country where it will be used in the fight against COVID-19.

Certification comes two months after CAE signed a contract with the Government of Canada to manufacture and supply 10,000 ventilators.

“Since the beginning of the pandemic, CAE was the first to receive certification from Health Canada for an entirely new ventilator. It was created and manufactured in Canada, and we are proud that it will help save lives in the fight against COVID-19,” said Marc Parent, CAE’s President and CEO. “The agility shown by CAE in designing and succeeding to have the CAE Air1 ventilator certified in a fraction of the usual time is a testament to the strength of CAE’s innovation, engineering talent, and advanced manufacturing capabilities. I am proud of our team for rising to this humanitarian challenge and strengthening Canada’s self-sufficiency in the medical field during these unprecedented times.”

CAE will now start shipping hundreds of CAE Air1 ventilators to the Government of Canada every week. The CAE Air1 ventilator can deliver pressure control, volume control and pressure support ventilation using room air or pressured oxygen. It uses an intuitive, simple touchscreen interface and is bundled with on-demand ventilator training, adaptive e-learning modules related to COVID-19 patient management, and 24/7 customer support. It will support Intensive Care Units patients treated for COVID-19.

“CAE, one of Canada’s leading aerospace firms, stepped up early on with their commitment to produce a made-in-Canada ventilator design that will help save the lives of COVID-19 patients battling the disease. Today’s announcement is a testament to CAE’s agility and innovative capability. I am glad that we were able to support CAE in accelerating the design and manufacturing of CAE Air1 ventilator that is now ready to be used by our frontline healthcare workers,” said the Honourable Navdeep Bains, Canada’s Minister of Innovation, Science and Industry.

SourceCAE

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”